Company intelligence / Profile preview
3SBio
Shenyang, China3sbio.com ↗
- Ownership
- Public · 1530
- Development stage
- Commercial
01
Overview
A leading Chinese biopharmaceutical company with five global production bases and over $N/A revenue. Market leader in thrombopoietin (64.8% share) and erythropoietin products in China. Operates dual biological/chemical drug platforms with >30 commercialized products.
- Therapeutic areas
- OncologyDermatologyImmunologyHematology
- Modalities
- Monoclonal antibodiesRecombinant proteinsSmall molecules
- Industry
- Biotech
02
Drug pipeline
21 assets20 more assets in the full pipeline.
03
Financials
- Market cap
- $4.8B
- Total revenue
- $2.7B
- Enterprise value
- $2.4B
Beyond the preview
Go deeper on 3SBio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 3SBio.